Lupus & antiphospholipid syndrome
Long-term safety and efficacy of the combination of belimumab and rituximab in the treatment of severe and refractory SLE: a preliminary report
Authors' conclusion
Long-lasting remission was observed in patients with SLE following combination treatment with rituximab and belimumab. We observed no significant hypogammaglobulinaemia and, notably, persistent reduction of DN B cells.
Study context
- Population
- Patients with severe treatment-refractory SLE who previously participated in the phase II Synbiose Study
- Participants
- 8 patients
- Outcome
- Long-term clinical remission
- Follow-up
- Median 6.8 years
Methodological detailslong-term extension of the phase II Synbiose Study, high-sensitivity flow cytometry
- Long-term extension of the phase II Synbiose Study
- High-sensitivity flow cytometry
Main finding
As reported in the abstract
Patients maintaining long-term clinical remission (of 8)
6
Patients with a major flare
2
Immunosuppression-free remission among those in remission
2
Continued belimumab among those in remission
4
Original publication
Long-term safety and efficacy of the combination of belimumab and rituximab in the treatment of severe and refractory SLE: a preliminary report. Lupus Sci Med. Published 12 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →